Search

everythinglearnresearchcommunity

for

Search:↓

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Lupus affects the body and skin, causing joint pain and skin issues that can be treated with steroids and antimalarial drugs.

The paper concludes that the 1982 criteria for diagnosing systemic lupus erythematosus need updating to improve accuracy and involve dermatologists in the process.

Steroids help hair regrowth, and minoxidil slows post-steroid hair loss, but effects are temporary.

imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.

Pregnancy can increase lupus activity, but careful planning and treatment can improve outcomes.

Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.

Tph cells are linked to the severity of systemic lupus erythematosus.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Minoxidil use in children may cause heart issues.

A risk prediction model can help diagnose systemic lupus erythematosus earlier in primary care.

Chemotherapy can cause permanent, non-reversible hair loss similar to pattern baldness.

COVID-19 vaccination may trigger lupus in some people.

SLE is more common among Nigerians than previously thought, especially in women, requiring early treatment.

Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.

Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.

No systemic treatment for alopecia areata has strong evidence of effectiveness.

Systemic glucocorticosteroids are a primary treatment for various skin conditions but require careful management due to potential side effects and relapses.

Hair loss in lupus patients indicates higher disease activity.

Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

SLE patients in eastern Saudi Arabia have a generally good prognosis despite multi-organ involvement.

Systemic Lupus Erythematosus has varied symptoms and is hard to diagnose, affecting many body parts and requiring careful clinical judgment.

The document concludes that anti-dsDNA antibodies are not unique to SLE and their use as indicators is doubtful, highlighting the need for better understanding and classification of the disease.

Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.

Systemic corticosteroids don't prevent severe alopecia areata from spreading or relapsing.

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.

Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.

Systemic diseases can cause hair loss, which is often reversible with treatment.